Gene therapy for established murine collagen-induced arthritis bylocal and systemic adenovirus-madiated delivery of interleukin-4

To determine whether IL-4 is therapeutic in treating established experimental arthritis, a recombinant adenovirus carrying the gene that encodes murine IL-4 (Ad-mlL-4) was used for periarticular injection into the ankle joints into mice with established collagen-induced arthritis (CIA). Periarticular injection of Ad-mlL-4 resulted in a reduction in the severity of arthritis and joint swelling compared with saline and adenoviral control groups. Local expression of IL-4 also reduced macroscopic signs of joint inflammation and bone erosion. Moreover, injection of Ad-mlL-4 into the hind ankle joints resulted in a decrease in disease severity in the untreated front paws. Systemic delivery of murine IL-4 by intravenous injection of Ad-mlL-4 resulted in a significant reduction in the severity of early-stage arthritis.